Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

Jianghao Chen(Zero to Three), Ling Wang(Xijing Hospital), Ting Wang(Jilin University), Dong Li(Tongji University), Qing Yao(Tianjin Meteorological Bureau), Jing Wang(Shandong University), Ming Yu(Children's Hospital of Philadelphia), Juliang Zhang(Xijing Hospital), Yi Huan(Fujian Medical University), Xiaodong Zhou(Wenzhou Medical University)
BMC Cancer
May 21, 2013
Cited by 36


Related Papers